Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
SGRY vs DBVT vs ALKS vs USPH vs SEM
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Care Facilities
Medical - Care Facilities
SGRY vs DBVT vs ALKS vs USPH vs SEM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Biotechnology | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $1.87B | $1712.35T | $5.90B | $897M | $2.04B |
| Revenue (TTM) | $3.34B | $0.00 | $1.56B | $695M | $5.52B |
| Net Income (TTM) | $-76M | $-168M | $153M | $11M | $134M |
| Gross Margin | 22.8% | — | 65.4% | 22.0% | 10.6% |
| Operating Margin | 11.8% | — | 12.3% | 12.2% | 5.8% |
| Forward P/E | 38.0x | — | 24.8x | 20.6x | 13.1x |
| Total Debt | $4.02B | $22M | $70M | $426M | $3.70B |
| Cash & Equiv. | $240M | $194M | $1.12B | $36M | $27M |
SGRY vs DBVT vs ALKS vs USPH vs SEM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Surgery Partners, I… (SGRY) | 100 | 106.8 | +6.8% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
| U.S. Physical Thera… (USPH) | 100 | 79.6 | -20.4% |
| Select Medical Hold… (SEM) | 100 | 189.2 | +89.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SGRY vs DBVT vs ALKS vs USPH vs SEM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, SGRY doesn't own a clear edge in any measured category.
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs SGRY's -38.2%
ALKS has the current edge in this matchup, primarily because of its strength in sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- 9.8% margin vs SGRY's -2.3%
- 5.4% ROA vs DBVT's -89.0%
USPH is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 5 yrs, beta 0.93, yield 3.1%
- Rev growth 16.3%, EPS growth -22.8%, 3Y rev CAGR 12.2%
- Beta 0.93, yield 3.1%, current ratio 1.01x
- 16.3% revenue growth vs DBVT's -100.0%
SEM ranks third and is worth considering specifically for long-term compounding.
- 158.5% 10Y total return vs USPH's 22.6%
- Lower P/E (13.1x vs 20.6x)
- Beta 0.46 vs DBVT's 1.26
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (13.1x vs 20.6x) | |
| Quality / Margins | 9.8% margin vs SGRY's -2.3% | |
| Stability / Safety | Beta 0.46 vs DBVT's 1.26 | |
| Dividends | 3.1% yield, 5-year raise streak, vs SEM's 1.5%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs SGRY's -38.2% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
SGRY vs DBVT vs ALKS vs USPH vs SEM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SGRY vs DBVT vs ALKS vs USPH vs SEM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
DBVT leads 1 • SEM leads 1 • USPH leads 1 • SGRY leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SEM and DBVT operate at a comparable scale, with $5.5B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to SGRY's -2.3%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.3B | $0 | $1.6B | $695M | $5.5B |
| EBITDAEarnings before interest/tax | $572M | -$112M | $212M | $107M | $465M |
| Net IncomeAfter-tax profit | -$76M | -$168M | $153M | $11M | $134M |
| Free Cash FlowCash after capex | $208M | -$151M | $392M | $67M | $117M |
| Gross MarginGross profit ÷ Revenue | +22.8% | — | +65.4% | +22.0% | +10.6% |
| Operating MarginEBIT ÷ Revenue | +11.8% | — | +12.3% | +12.2% | +5.8% |
| Net MarginNet income ÷ Revenue | -2.3% | — | +9.8% | +1.5% | +2.4% |
| FCF MarginFCF ÷ Revenue | +6.2% | — | +25.1% | +9.6% | +2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.5% | — | +28.2% | +7.7% | +5.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.7% | +91.5% | -4.1% | -115.0% | -18.2% |
Valuation Metrics
Evenly matched — SGRY and SEM each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 13.9x trailing earnings, SEM trades at a 66% valuation discount to USPH's 41.5x P/E. On an enterprise value basis, SGRY's 10.0x EV/EBITDA is more attractive than ALKS's 17.3x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.9B | $1712.35T | $5.9B | $897M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $5.7B | $1712.35T | $4.9B | $1.3B | $5.7B |
| Trailing P/EPrice ÷ TTM EPS | -23.46x | -0.76x | 24.76x | 41.55x | 13.93x |
| Forward P/EPrice ÷ next-FY EPS est. | 37.99x | — | — | 20.63x | 13.06x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 10.00x | — | 17.25x | 12.52x | 12.04x |
| Price / SalesMarket cap ÷ Revenue | 0.57x | — | 4.00x | 1.15x | 0.37x |
| Price / BookPrice ÷ Book value/share | 0.52x | 0.66x | 3.28x | 1.16x | 1.00x |
| Price / FCFMarket cap ÷ FCF | 9.57x | — | 12.28x | 14.71x | 5.33x |
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to SEM's 1.82x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.2% | -130.2% | +8.8% | +1.4% | +6.6% |
| ROA (TTM)Return on assets | -0.9% | -89.0% | +5.4% | +0.9% | +2.3% |
| ROICReturn on invested capital | +4.1% | — | +18.9% | +5.6% | +4.8% |
| ROCEReturn on capital employed | +5.2% | -145.7% | +14.2% | +7.6% | +7.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 7 | 5 | 5 |
| Debt / EquityFinancial leverage | 1.14x | 0.13x | 0.04x | 0.55x | 1.82x |
| Net DebtTotal debt minus cash | $3.8B | -$172M | -$1.0B | $390M | $3.7B |
| Cash & Equiv.Liquid assets | $240M | $194M | $1.1B | $36M | $27M |
| Total DebtShort + long-term debt | $4.0B | $22M | $70M | $426M | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | 1.35x | -189.82x | 32.30x | 15.42x | 4.41x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $2,773 for SGRY. Over the past 12 months, DBVT leads with a +110.4% total return vs SGRY's -38.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs SGRY's -25.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.2% | +4.9% | +25.3% | -24.6% | +11.4% |
| 1-Year ReturnPast 12 months | -38.2% | +110.4% | +16.5% | -14.3% | +11.1% |
| 3-Year ReturnCumulative with dividends | -59.2% | +19.7% | +14.5% | -43.7% | +7.4% |
| 5-Year ReturnCumulative with dividends | -72.3% | -69.1% | +60.9% | -43.4% | -11.1% |
| 10-Year ReturnCumulative with dividends | -0.6% | -87.0% | -11.0% | +22.6% | +158.5% |
| CAGR (3Y)Annualised 3-year return | -25.8% | +6.2% | +4.6% | -17.4% | +2.4% |
Risk & Volatility
SEM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SEM is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEM currently trades 96.8% from its 52-week high vs SGRY's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 1.26x | 1.06x | 0.93x | 0.46x |
| 52-Week HighHighest price in past year | $24.18 | $26.18 | $36.60 | $93.50 | $16.99 |
| 52-Week LowLowest price in past year | $11.41 | $7.53 | $25.17 | $58.55 | $11.65 |
| % of 52W HighCurrent price vs 52-week peak | +59.2% | +76.3% | +96.7% | +63.1% | +96.8% |
| RSI (14)Momentum oscillator 0–100 | 63.3 | 48.1 | 60.2 | 46.1 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 252K | 2.3M | 171K | 2.1M |
Analyst Outlook
USPH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SGRY as "Buy", DBVT as "Buy", ALKS as "Buy", USPH as "Buy", SEM as "Hold". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 9.5% for SEM (target: $18). For income investors, USPH offers the higher dividend yield at 3.06% vs SEM's 1.55%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $18.60 | $46.33 | $44.00 | $102.00 | $18.00 |
| # AnalystsCovering analysts | 22 | 15 | 28 | 12 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +3.1% | +1.5% |
| Dividend StreakConsecutive years of raises | 0 | 0 | 0 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $1.80 | $0.25 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | +0.6% | +4.9% |
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 1 (Total Returns). 1 tied.
SGRY vs DBVT vs ALKS vs USPH vs SEM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SGRY or DBVT or ALKS or USPH or SEM a better buy right now?
For growth investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Select Medical Holdings Corporation (SEM) offers the better valuation at 13. 9x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Surgery Partners, Inc. (SGRY) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SGRY or DBVT or ALKS or USPH or SEM?
On trailing P/E, Select Medical Holdings Corporation (SEM) is the cheapest at 13.
9x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, Select Medical Holdings Corporation is actually cheaper at 13. 1x.
03Which is the better long-term investment — SGRY or DBVT or ALKS or USPH or SEM?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -72. 3% for Surgery Partners, Inc. (SGRY). Over 10 years, the gap is even starker: SEM returned +158. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SGRY or DBVT or ALKS or USPH or SEM?
By beta (market sensitivity over 5 years), Select Medical Holdings Corporation (SEM) is the lower-risk stock at 0.
46β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 173% more volatile than SEM relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 182% for Select Medical Holdings Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — SGRY or DBVT or ALKS or USPH or SEM?
By revenue growth (latest reported year), U.
S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Surgery Partners, Inc. grew EPS 54. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, USPH leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SGRY or DBVT or ALKS or USPH or SEM?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -2. 4% for Surgery Partners, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SGRY or DBVT or ALKS or USPH or SEM more undervalued right now?
On forward earnings alone, Select Medical Holdings Corporation (SEM) trades at 13.
1x forward P/E versus 38. 0x for Surgery Partners, Inc. — 24. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — SGRY or DBVT or ALKS or USPH or SEM?
In this comparison, USPH (3.
1% yield), SEM (1. 5% yield) pay a dividend. SGRY, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is SGRY or DBVT or ALKS or USPH or SEM better for a retirement portfolio?
For long-horizon retirement investors, Select Medical Holdings Corporation (SEM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
46), 1. 5% yield, +158. 5% 10Y return). Both have compounded well over 10 years (SEM: +158. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SGRY and DBVT and ALKS and USPH and SEM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SGRY is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; USPH is a small-cap high-growth stock; SEM is a small-cap deep-value stock. USPH, SEM pay a dividend while SGRY, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.